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In the initial characterization ofthe role played by IL-2 during immune responses
many investigators questioned how an antigen-nonspecific lymphocytotrophic hor-
mone could promote an antigen-dependent clonal expansion ofT cells. However,
when IL-2 receptors were found to be expressed primarily following antigen activa-
tion, it was immediately apparent that the T cell antigen receptor complex deter-
mines which clones become responsive to IL-2 (reviewed in reference 1). In contrast,
NK cells respond to IL-2 without any prior antigenic stimuli, as evidenced by an
increased capacity to lyse a variety of target cells (2-4). NK cells are thought to be
responsible for much ofthe therapeutic efficacy oflymphokine-activated killer cells
(LAK),' currently being used for cancer treatment (5, 6). In addition, some cells
in freshly isolated PBL populations may also be capable ofproliferating in response
toIL-2, even in the absence ofexogenousantigen activation (7). However, precisely
what proportion ofcirculatingcells are IL-2 responsive, and which cell types among
themixture ofT cells, B cells, and NKcells actually account for this IL-2 reactivity
have remained obscure.
It is now accepted that the IL-2 receptor is comprised ofat least two chains, one
75-kD (p75) and another 55 kD (p55) (8-12). Each chain can be expressed in its
isolated formor noncovalentlycombined as a heterodimer(1). ThecDNAencoding
these proteins have been cloned and sequenced, revealing that both chains have ex-
tracellular domains of -215 residues. In addition, the p75 chain has a large in-
This work wassupported by National Institutes ofHealth grants CA-41619 andCA-17643, and by The
Council forTobacco Research, U. S. A., Inc. grant 1715. M. A. Caligiuriwas supportedby theClaudia
Adams Barr Investigation in Cancer Research.
Addresscorrespondence to Dr. Jerome Ritz, Division ofTumor Immunology, Dana-Farber Cancer
Institute, 44 Binney Street, Boston, MA 02115.
J. EXP. MED. 0 The Rockefeller University Press - 0022-100719010511509118 $2.00
￿
1599
Volume 171 May 1990 1509-15261510
￿
INTERLEUKIN 2 RECEPTORS IN RESTING LYMPHOCYTES
tracytoplasmic domain (286 residues), while the p55 chain has only a small(13 residues)
cytoplasmic anchor (13-16). This structural information is consistent with functional
data, which indicate that the p75 chain participates in signal transduction in both
its isolated and heterodimeric form, whereas the p55 chain only serves to facilitate
IL-2 binding. When expressed together on the cell surface, the p75 chain and the
p55 chain associate noncovalently to form the high affinity IL-2 receptor (Ki =
10-x ' M). By comparison, when constitutively expressed in its isolated form, the
p75 chain binds IL-2 with intermediate affinity (K~i = 10 -`' M), while the nonfunc-
tional isolated p55 chain binds IL-2 with low affinity (Ki = 10 -s M) (17).
Elucidation of the structure of the IL-2 receptor has been facilitated by the devel-
opment of various mAbs directed against the receptor itself. Anti-p55 mAb (CD25)
block the binding of IL-2 to the high affinity IL-2 receptor by disrupting the non-
covalently bound heterodimer, thereby creating isolated p75 chains to which IL-2
binds with intermediate affinity (17). Recently, Takeshita et al. isolated a mAb (TU27)
which competitively inhibits radiolabeled IL-2 binding, both to the high affinity IL-2
receptor and to the isolated intermediate affinity p75 chain (18). Tsudo et al. have
also developed mAbs reactive with the p75 chain both in its isolated intermediate
affinity and heterodimeric high affinity form (19), and in collaboration with
Hatakeyama et al. these antibodies were used to isolate and clone cDNA encoding
the p75 chain (16).
With the availability ofmAbs reactive with both components ofthe IL-2 receptor,
and cDNA encoding both receptor chains, we examined the expression ofthe different
IL-2 receptor chains on purified lymphocyte populations in unstimulated periph-
eral blood . Our results, detailed in this report, indicate that most T cells (>98%)
express neither the high affinity IL-2 receptor nor the functional intermediate affinity
p75 chain of the IL-2 receptor without prior activation. In contrast, most resting
NK cells, which make up -10 0 /c of PBMC, express the isolated intermediate affinity
p75 IL-2 receptor. In addition, a subpopulation ofNK cells, distinguished by a high
density expression of the NKH1 molecule, constitutively express both the p75 and
p55 chain, thus forming the high affinity IL-2 receptor. These cells exhibit a brisk
proliferative response to IL-2, similar to that seen with antigen-activated T cells,
yet do so in the absence of any known antigenic stimuli.
Materials and Methods
'1'I-IL-2 Binding Studies.
￿
Binding of radioiodinated IL-2 was performed as described pre-
viously (17), except that 10' cells/tube were used for unactivated PBMC, whereas 10°
cells/tube were used for cellsactivated with anti-CD3 for 72 h. Radioiodinated IL-2 was pre-
pared with two different specific activities (10' cpm/pmol and 105 cpm/pmol) so that binding
assays could be carried out at IL-2 concentrations ranging from 1 pM to 100 nM . The number
of intermediate affinity p75 IL-2 receptor binding sites was determined by performing the
1'251-IL-2 binding assay in the presence of a saturating concentration of anti-p55 as described
previously (17).
Isolation and Activation of Cell Populationsfor Northern Blot Analysis.
￿
PBMC were obtained
from the blood of normal individuals by Ficoll/Hypaque centrifugation and cultured at 10°
cells/ml in RPMI 1640 medium containing 10% FCS supplemented with giutamine and an-
tibiotics. PBMC were then activated with soluble anti-CD3 (OKT3 ; Ortho Diagnostic Systems,
Raritan, NJ) at a 1 :10,000 dilution. An enriched T cell population was obtained from PBMC
using a modification of the method of Theile and Lipsky (20) to remove.macrophages and
NK cells, as well as positive selection with anti-CD3 to retain T cells. PBMC were resuspendedCALIGIURI ET AL.
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at 5 x 106 cells/ml in serum free medium containing 5 MM t.-leucine methyl ester hydro-
chloride (Sigma Chemical Co., St. Louis, MO) and incubated at 22°C for 60 min. This pro-
cedure selectively lyses monocytes and NK cells (20). Cells were washed twice with serum-
containing medium, then incubated with 5 gg/ml anti-CD3 mAb (64.1; a generous gift of
Dr. E. Vitetta, University of Texas Health Science Center at Dallas) for 60 min at 4°C. Un-
bound antibody was removed by spinning cells over a layer of FCS. Cells were incubated
on goat anti-mouse Fc-coated petri dishes for 60 min at 4°C. Unbound cells were removed
by gentle aspiration and washed 3 x with cold media. Adherent T cells were immediately
harvested for t = 0 RNA isolation, and adhered aliquots were subsequently incubated at
37°C for 24 h to initiate T cell activation.
RNA Isolation and Quantitation.
￿
Total cellular RNA was isolated from cells by a modification
of the method of Ausubel et al. (21). Cells were washed with normal saline and suspended
in 7.5 ml cold lysis buffer: 4 M guanidine thiocyanate, 20 mM sodium acetate (pH 5.2),
150 mM 2-a-mercaptoethanol, and 0.4% Sarkosyl. The lysate was sheared through a syringe
containing an 18 g needle and layered over 2.5 ml of a 5.7 M cesium chloride and 25 mM
sodium acetate (pH 5.2) solution. RNA was pelleted at 160,000g at 20°C for 20 h. The RNA
pellet was resuspended in water and ethanol, precipitated overnight at -20°C, pelleted by
centrifugation, and resuspended in water. Total RNA was quantified by measuring A260/280.
Hybridization Analysis.
￿
15 p.g total RNA was denatured with formaldehyde (10 m 70°C),
fractionated by electrophoresis through 1 % agarose gels containing 2.2 M formaldehyde and
visualized by ethidium bromide staining to assess the integrity of the RNA and to verify
that equal amounts of RNA were loaded in all wells. The RNA was transferred to nitrocellu-
lose filters by capillary transfer in 10 x SSC (1 x SSC = 0.15 M NaCl plus 0.015 M sodium
citrate, pH 7 .0). The filters were vacuum baked at 80°C for 90 min. Prehybridizations and
hybridizations were carried out for 22 and 72 h, respectively, at 42° C in a solution containing
50% formamide, 5 x SSC, 5 x Denhardt's solution, 0.2% SDS, and 100,ug/ml of heat dena-
tured sheared salmon sperm DNA. DNA fragments were :,2p labeled by the oligonucleotide
primed elongation method (22) and 1 .5 x 106 cpm of heat denatured :12P-labeled probes
(specific activity 10"cpm/Wg DNA) were added per milliliter of hybridization solution. Filters
were washed 10 min at room temperature with 1 x SSC and 0 .1% SDS, 30 min at 42°C with
0.1 SSC and 0.1% SDS and 30 min at 60°C with 0.2 x SSC and 0.1% SDS, air dried, and
exposed to Kodak XAR-5 film using Dupont Cronex intensifying screens. The autoradio-
graphs were scanned with an EC densitometer (EC Apparatus Corp., St. Petersburg, FL)
using a Hewlett Packard 3390 integrator (Palo Alto, CA). The p75 cDNA probe was removed
from the nitrocellulose filter by treatment with 0.1 x SSC and 0.1% SDS at 100°C for 20
min before subsequent p55 hybridization. Plasmid pBS02 containing a full-length human
p75 chain cDNA was obtained from Dr. Warren Leonard (National Institutes of Health,
Bethesda, MD). pBS02 was cleaved with Eco RI to generate a 1.8-kb fragment that was purified
from agarose gels. Plasmid pKCR Tac-2a, containing a full-length human p55 chain cDNA
was obtained from Dr. Tasaku Honjo (Kyoto University, Kyoto, Japan), and was cleaved with
Hind III to generate a 2 .9-kb fragment.
Monoclonal Antibodies (mAb).
￿
NKHI (anti-CD56), BI (anti-CD20), IL-2R (anti-CD25),
TI (anti-CD5), T4 (anti-CD4), and T8 (anti-CD8) are commercially available from Coulter
Immunology (Hialeah, FL). TU 27-FITC (anti-p75) was the generous gift of Dr. Kazuo
Sugamura (18, 23). T12 is a pan-T cell antibody (anti-CD6) from our laboratory previously
described (24).
Immunofluorescence Studies.
￿
PBL were obtained from fresh blood after Ficoll-Hypaque sepa-
ration and adherence to plastic for 1 h at 37°C . PBL were 82% ± 1 .9 CD3' for six indi-
viduals. For T cell phenotypic analysis, cells were then washed twice and stained with an
anti-CD3 mAb directly conjugated to phycoerythrin (CD3-RDI) and TU-27-FITC (anti-
p75) or CD3-RD1 and IL-2R-FITC (anti-p55). Similar staining was performed with CD5-
RDl instead of CD3-RD1 with identical results (not shown). To obtain similar numbers of
NK cells, nonadherent PBL were first depleted of mature T cells using anti-CD6 mAb cou-
pled to immunomagnetic beads (Coulter Immunology), and then stained with NKHI-RD1
and sorted for NKHI' cells on an EPICS 752 flow cytometer (Coulter Electronics, Hialeah,
FL). Sorted cells, which were 92% ± 9.2 NKHI' for five individuals, were then stained with
either TU-27-FITC (anti-p75) or IL-2R-FITC (anti-p55). For phenotypic studies performed151 2
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on CD4' T cells, freshly isolated PBMC were depleted of monocytes by adherence for 1 h
at 37°C and then 106 cells were labeled with T4-RDI and IL-2RFITC or with T4-RDI and
TU27-FITC. 104 CD4' cells were then analyzed for their reactivity with IL-2R-FITC and
TU27-FITC. The same procedure was repeated for CD8' T cells using T8-RDI, except that
these cells were first depleted of NKHI' cells (which can also express CD8) using NKHI
coupled to magnetic beads (Dynabeads, Fort Lee, NJ). Background immunofluorescence using
nonreactive directly conjugated mAbs Mslg-FITC and Mslg-RDI was <1% for all analyses.
Populations of NKHlbr'sh, ' and NKHId'n,' cells were separated on the basis of visually defined
boundaries of staining intensity as seen in Fig. 5 and as previously described (25). Variation
between five different donors was minimal. Since CD6' T cells were depleted by immuno-
magnetic beads before immunofluorescent cell sorting of NKHI' cells, purified NK popu-
lations did not contain cells that coexpressed CD3 .
Proliferation Assays.
￿
Sorted populations oflymphocytes were plated shortly after their iso-
lation from resting human peripheral blood in U-bottomed wells at a concentration of 15-25 x
103 cells/well in RPMI 1640 with 18% human AB serum in the presence of varying concen-
trations of rIL-2 (sp act 1.5 x 10' U/mg protein; Hoffmann-La Roche, Inc., Nutley, NJ).
Cells were incubated at 37°C for either 4 or 7 d as specified below and proliferation was
measured in triplicate by methyl-[3H]thymidine incorporation. Anti-p55 (26) was used as
sterile mouse ascites in blocking studies at a 1 :400 dilution. Ascites from a nonreactive mu-
rine hybridoma was used as a control in blocking studies at a 1 :400 dilution. Each mAb was
added 30 min before the addition of rIL-2.
Cytotoxicity Assays.
￿
Sorted NKHlbr'sn" and NKHld""' cells were plated in V-bottomed
wells in RPMI 1640 with 5% FCS at a concentration of 4 x 103 cells/well. Assays were then
placed in media alone or media supplemented with 10 pM or 10 nM rIL-2 and incubated
at 37°C for 18 h, at which time 4 x 103 5'Cr-labeled K562 target cells were added to each
well. Plates were then centrifuged and incubated for an additional 4 h at 37°C . Chromium
release assays were then performed as described previously (27).
Results
IL-2 Binding to Resting andActivated PBMC.
￿
To characterize the unstimulated pe-
ripheral blood cells capable of responding to IL-2, we first assayed resting freshly
isolated PBMC for IL-2 binding sites after optimizing the sensitivity of the radiola-
beled IL-2 binding assay to detect small numbers of binding sites. Results in Table
I show that freshly isolated PBMC express very low levels of all three classes of IL-2
binding sites, including the high affinity IL-2 receptor, intermediate affinity p75
chains, and isolated low affinity p55 chains. The number of intermediate affinity
sites was determined by radiolabeled IL-2 binding assays performed in the presence
of anti-p55 mAb (17) . It is therefore likely that at least some of the p75 chains de-
tected are, if fact, expressed as part of the high affinity heterodimer. However, when
compared with the number ofhigh affinity IL-2 receptor sites, a small but significantly
greater number of isolated intermediate affinity p75 sites was detected, suggesting
TABLE I
IL-2R Binding Sites on Unstimulated and Stimulated Human PBMC
High Intermediate Low
Activation affinity affinity
￿
affinity
signal
￿
(p75/p55)
￿
(p75)
￿
(p55)
None
￿
53 ± 5*
￿
177 ± 40
￿
1,080 ± 325
Anti-CD3
￿
1,099 ± 135
￿
1,452 ± 373
￿
8,993 ± 1,802
* The values shown represent mean sites per cell ± SEM for 4 to 7 separate
experiments .CALIGIURI ET AL.
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that at least some p75 chains are expressed in their isolated form within the resting
PBMC pool .
The interactions of various IL-2 receptors within theT cell population was fur-
ther evaluated by performing similar binding assays after activation with anti-CD3 .
As shown in Table I, an eightfold increase in the number of both p55 sites and p75
sites occurs after CD3 activation . However, in contrast to restingPBMC, it is likely
that almost all available p75 chains noncovalently bind with the excess p55 chains
to form the high affinity IL-2 receptor after CD3 activation, as there is no statistical
difference between the number of high affinity sites compared with the number of
intermediate affinity p75 IL-2 receptor sites detected .
Expression ofIL-2 ReceptormRNA in Resting andActivatedPBMC.
￿
To assess the qualita-
tive distribution of the different IL-2 receptors on the various cells within PBMC
before and after activation, we next examined freshly isolated PBMC and purified
restingT cells for their expression ofp75 and p55 IL-2 receptor mRNA using Northern
blot analysis . Previous work from other laboratories suggested that resting T cells
constitutively express the p75 chain of the IL-2 receptor, while only the p55 chain
is actively synthesized after antigen activation to form the high affinity IL-2 receptor
(28) . As can be seen in Fig . 1 A, unstimulated PBMC contained low but significant
amounts of p75mRNA . However, after depletion of both monocytes and NK cells,
p75 mRNA transcripts were barely detectable, indicating that the majority of p75
mRNA is expressed within the non-T cell compartment of resting PBMC . After ac-
tivation of either PBMC or purified T cells with anti-CD3, there is a marked in-
crease in the level of expression of p75mRNA within 24 h, corresponding to similar
increases in the surface expression of the p75 chain detected by IL-2 binding. When
the same Northern blots were hybridized with a p55-specific probe, p55mRNA was
not detected in either PBMC or purified T cells (Fig. 1 B) . However, 24 h after CD3
activation, p55 mRNA was readily detected in both populations. In other experi-
ments not shown, very low levels of p55 mRNA were detectable in resting PBMC
after prolonged exposure of the Northern blots . In all experiments, p55 mRNA was
consistently less prevalent than p75 mRNA in unstimulated PBMC .
Expression ofp55 andp75 IL-2 Receptor in UnstimulatedPBL.
￿
To determine whether
p75mRNA is translated into a stably expressed protein product and to identify the
cells in resting peripheral blood that constitutively express p75, weexamined resting
FIGURE 1 .
￿
Northern blot analysis ofIL-2 receptor
p75(A)andp55 (B) expression in restingandCD3-
activated populations ofhumanPBMC andpurified
T cells . Cells were isolated as described in Materials
andMethods . Total RNAwas harvested from resting
cells (t = 0) or after an incubation in the presence
of anti-CD3 antibodies at 37°C for 24 h . 15 1~g of
totalRNA per lane was subjected to Northern blot
analysis. Thep75(A) hybridization probe used de-
tected a specificmRNA of4.0 kb .Thep55 (B)cDNA
probe detected mRNAs of 3.5 and 1.5 kb in length .
p75 andp55 blots were exposed using intensifying
screens for 20 and 48 h, respectively.151 4
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T cell and purified NK cell populations using flow cytometry. An example from
a single individual is shown in Fig. 2 . Dual immunofluorescence ofCD3 versus p75
or p55 revealed that resting CD3+ cells have no detectable p75, and only a very
small number of cells express p55 . In contrast, ti50% of NKHI' cells in this in-
dividual expressed p75, while p55 expression was very low, similar to that seen on
restingT cells . Similar studies carried out on six individuals confirmed these findings,
showing that only 0 .2% ± 0.5 of resting CD3+ T cells express p75 and only 1 .8%
± 0.6 of resting CD3` T cells express p55 . In contrast, 28.9% ± 19.8 of NKHI'
cells express p75, while only 1.4% ± 1 .1 ofNK cells express p55 . An analysis of
IL-2 receptor expression within the CD8' and CD4' T cell subsets was also per-
formed (Fig . 3), showing that 6% of CD4' cells constitutively expressed the iso-
lated p55 chain, while p55 was not expressed in the CD8' subset . Isolated p75 IL-2
receptorwas not detectable on either subset . It should be noted that CD8' NK cells
(which expressCD8 in low density), were first removed using immunomagnetic bead
depletion with NKHI mAb before immunofluorescence analysis . Thus, the pheno-
typic analyses demonstrate that the vast majority ofT cells found in restinghuman
peripheral blood lack expression of both p55 and p75 chains of the IL-2 receptor.
FIGURE 2 .
￿
Two-color immunofluorescence analysis ofresting peripheral blood lymphocyte sub-
populations . For T cell analysis, nonadherent PBL were directly stained with phycoerythrin-
conjugated anti-CD3 (CD3-RDI) and anti-p55-FITC (A), or anti-p75-FITC (B) . NK cell popu-
lations were first purified from peripheral blood by sorting forNKHI' cells (using NKHI-RDI),
and then stained with either anti-p55-FITC (C); or anti-p75-FITC (D) before two-color analysis .
Note the biphasic intensity ofNKHI staining. Actual values are as follows : (A) CD3'p55 - 72% ;
CD3'p55' 3% ; CD3-p55* 0% ; (B) CD3'p75' 0% ; CD3-p75' 4% ; (C) NKHI'p55 - 89% ;
NKH1'p55' 3% NKHI -p55' 0% ; (D) NKHI'p75- 46% ; NKHI'p75' 46% ; NKHI -p75* 0% .s
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FIGURE 3.
￿
Two-color immunofiuorescence analysis T cell subpopulations. CD4' or CD8' T
cells were stained and analyzed. (A) CD4vs. p55; (B) CD4 vs. p75; (C)CD8 vs. p55; (D) CD8
vs. p75. Note minimal (6%) staining of CD4* cells with anti-p55 (A). The remaining T cell
subsets shown were negative for IL-2 receptor expression.
In striking contrast, a significant fraction of NK cells isolated from the resting PBMC
population constitutively express the isolated intermediate affinity p75 IL-2 receptor,
while expression ofthe p55 chain is limited to a very small fraction within this popu-
lation.
Proliferation of Unstimulated PBL to Exogenous IL-2.
￿
To assess the functional sig-
nificance of IL-2 receptor expression by T cellsand NK cells, we examined the prolifer-
ative response ofpurified populations at increasing doses of IL-2 without additional
activation stimuli. As shown in Fig. 4, T cells consistently display a very low degree
of proliferation, as determined by (3Hlthymidine incorporation when compared
with equal numbers of NK cells. This result was evident at high IL-2 concentra-
tions, including those that saturate both high and intermediate affinity binding sites.
In addition, it is evident that NK proliferation was noted at an IL-2 concentration
of only 10 pM. Since this concentration of IL-2 saturates 50% ofhigh affinity IL-2
receptor and <157o of isolated intermediate affinity receptors, it effectively stimu-
lates cells solely via the high affinity IL-2 receptor (17). Given this discrimination,
it is noteworthy that there is a significant NK cell response at this concentration,
and that this response was fivefold greater than that ofpurified T cells that remained
essentially unchanged compared with proliferation in media alone. Moreover, when
a 10-fold higher IL-2 concentration (100 pM) was used to saturate all high affinity
IL-2 receptors and -10% of any isolated intermediate affinity p75 IL-2 receptors1516
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(17), there was a marked increase in NK cell proliferation, again without any significant
increase in T cell proliferation. 50% maximal proliferation was noted at 50 pM,
a concentration that saturates nearly all high affinity sites and <5% of intermediate
affinity sites. Further increases in the concentration of IL-2 to 5 nM, which results
in -85% saturation of the isolated intermediate affinity p75 IL-2 receptor (17), did
not result in further increases in NK cell proliferation and actually resulted in a
slight decrease. Collectively, these data suggested that a fraction of NK cells express
the heterodimeric high affinity IL-2 receptor, which when saturated, accounts for
much of the proliferation seen within the entire NK cell population.
Expression oftheHighAffinity IL-2 Receptor inRestingPBL. In previous studies (29),
the NK cell population, purified from resting PBMC, was found to be heteroge-
neous with regard to the cell surface density expression of the NKHI antigen. Two
populations have been identified: one with low surface density expression of the NKHI
antigen (NKH1d"n') and the other with higher surface density expression of NKHI
(NKH1 bright +). The NKHIbright + cells routinely make up <5'/'o of the entire NK cell
population and have been shown to lack expression of CD3 antigen. As shown in
Fig. 2, constitutive expression of the p75 chain is phenotypically equivalent in both
the NKHlbr'snt+ and NKHld"" + populations. Less than 2% of NK cells express
sufficient p55 to be detected by immunofluorescence, but this appeared to be pri-
marily within the NKHIbright+ fraction. Given that isolated p55 and p75 chains,
when simultaneously expressed, interact to form the heterodimeric high affinity IL-2
receptor, this suggested that the NKHlhr'Kh`+ population might express the high
affinity receptor in addition to isolated intermediate affinity p75, and that this high
affinity receptor might be responsible for the proliferation of NK cells seen at low
concentrations of IL-2.
To investigate this further, we sorted NKHI+ cells from fresh PBL into NKHlbrigh1+
and NKHIdin, + fractions based on the surface density expression of the NKHI an-
tigen as shown in Fig. 5 A . We next examined proliferation of sorted cells at a dose
ofrIL-2 (10 pM) that would saturate only the high affinity IL-2 receptors expressed
within each population (17). As can be seen in Fig. 5 B, the NKHlb"gh,+ cells iso-
lated from unstimulated peripheral blood showed over a 40-fold increase in
[3H]thymidine incorporation when compared with the NKHldin,+ cells that failed
to respond. Further evidence that this proliferation was promoted solely via the high
affinity IL-2 receptor is provided by the complete abrogation of proliferation seen
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FIGURE 4. Proliferative response of resting
populations T cells (")vs. NK (O)cells cultured
at varying concentrations of IL-2 for96 h. CD5'
T cells and NKH1' NK cells were purified by
immunofluorescent cell sorting as described in
MaterialsandMethods. Values displayed repre-
sent thepercent ofthe maximal [3H]thymidine
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(A) Expression ofNKHI antigen on
resting NK cells. Flow cytometric histograms
showingNKHI stainingofhigh density (bright)
and low density (dim) cells in peripheral blood
before (top) andafter (middle andbottom) the two
NKHI+ subpopulations were purified by cell
sorting. .(B) Proliferation of NKHld""+ and
NKHlb"g 1+ cells in response to low concentra-
tionsof rIL-2. Subpopulations of NKH1' cells
were isolated from freshPBLand then plated in
media aloneor in mediacontaining 10 pM rIL-
2 for96 h. Before theaddition ofIL-2, cells were
incubated for 30 min with either a nonreactive
mAbor anti-p55 mAb. cpm in mediaalone(246
t 70 for NKHIb"ghl+ and 227 t 67 for
NKHldin"+cells) were subtracted as background.
Results representthemean t SEMfortriplicate
samples.
after addition of anti-p55 mAb, which blocks binding of IL-2 to the high affinity
IL-2 receptor but not to the intermediate affinity p75 IL-2 receptor (17).
To further characterize the expression of functional high affinity IL-2 receptors
within resting human PBL, we next examined the proliferation of various purified
PBL populations as identified by lymphocyte specific antigens, again using 10 pM
ofIL-2 . As can be seen in Fig. 6, the only population to show significant prolifera-
tion after 5 d of culture were the NKHlbrigh` + cells. Only a minimal proliferative
response was seen in the NKHI dim+ population. This may be due to a small frac-
tion of cells expressing the high affinity IL-2 receptor within this population since
this activity is also completely abrogated in the presence of anti-p55. Most notably,
there is virtually no proliferation seen within either CD4+ or CD8+ T cell subsets
or the CD20+ B cell population.
Activation of NK Cells through the Isolated Intermediate p75 IL-2 Receptor.
￿
Prolifera-
tion within the NKHlbrigh,+ and NKHldim+ populations was next examined fol-
lowing a 96-h incubation period and at concentrations of IL-2 that selectively satu-
rated each ofthe twofunctional IL-2 receptors. A representative assayafter isolation
of these two populations from resting peripheral blood is shown in Fig. 7 A,1518
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FIGURE 6 .
￿
Proliferation of resting human
PBL subpopulations as measured by [3H]thy-
midine incorporation following a 96-h culture
in either media + a nonreactive mAb (/),
10 pM rIL-2 + a nonreactive mAb (N), or
10pM rIL-2 + anti-p55mAb (/). Purified
populations were isolated from resting periph-
eral blood using immunofluorescent cell sort-
ing . Results represent the mean f SEM for
triplicate samples .
and serves to illustrate several points . First, there is maximal proliferation in the
NKHlbrighl+ population at 100 pM IL-2, a concentration that saturates 100% of
high affinity IL-2 receptors and only -20% of intermediate affinity IL-2 receptors
(17) . In contrast, the NKHldim+ population, which expresses the isolated inter-
mediate affinity IL-2 receptor, shows little or no proliferation at this concentration .
This finding suggests that IL-2 binding to high affinity IL-2 receptors is entirely
responsible for the proliferation seen within the NKHl br ighc+ population . Second,
further increases in IL-2 concentrations that saturate 50% (1 nM) and 100% (10
nM) of isolated intermediate affinity p75 IL-2 receptors (17) fail to increase the prolifer-
ative response in the NKHlbr igh ` + population . Surprisingly, the NKHldim+ cells,
which lack the high affinity IL-2 receptor but constitutively express the intermediate
affinity p75 IL-2 receptor, showed only minimal increases in proliferation at these
high concentrations of IL-2 . In separate experiments, absolute cell counts were found
to correlate closely with results of the [3H]thymidine proliferation assay. After 7 d
of in vitro culture with either 1 or 10 nM rIL-2, there was only a twofold increase
in the number of NKHldim+ cells, while the NKHIbrigh,I cells showed more than
a 15-fold increase in cell number (data not shown) .
The constitutive expression of a functional isolated intermediate affinity p75 IL-2
receptor on NKHldim+ cells was verified by examining non-MHC-restricted cyto-
toxicity following 18-h incubations in the presence or absence of increasing concen-
trations of rIL-2 (Fig . 7 B) . While a minimal increase in cytotoxicity against K562
target cellswas noted with 10 pM rIL-2, a more substantial increase in cytotoxicity
was seen at IL-2 concentrations (10 nM)that saturate intermediate affinity p75 IL-2
receptors . It is noteworthy that NKHl brigh,1 cells also show enhanced cytotoxicity
at these higher doses of rIL-2, consistent with phenotypic studies that demonstrate
a relative excess of isolated intermediate affinity p75 receptor compared with the
expression of high affinity IL-2 receptors within this select population .
Discussion
The present study characterizes the consequences of IL-2 receptor expression by
resting human peripheral blood cells by identifying which cells express receptors
andby determining the functional responses of these cells to varying concentrationsCALIGIURI ET AL .
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FIGURE 7 .
￿
(A) Proliferative response of resting populations of NKHlb"gh,, (M) and NKHldim+
(p) cells cultured in varying concentrations ofIL-2 for 96 h . Values displayed represent the per-
cent of the maximal [3Hlthymidine incorporation t SEM for triplicate samples . (B) Cytotoxicity
of NKHlbrigh,, (0)and NKHldi,+ (®) cells . Effector populations were first cultured overnight
in either media, 10 pM HL-2 or 10 nM rIL-2 . "Cr-labeled K562 targets were then added to
each well at an E/T ratio of 1 :1, and incubated foran additional 4h . Results represent themean
percent lysis ± SEM for triplicate samples .
of IL-2 . Previous studies have shown that antigen activation of resting T cells results
in the expression of high affinity IL-2 receptors which then signal the proliferation
of antigen-selected cells (1) . The expression of a functional IL-2 receptoron unacti-
vated or resting populations ofT cells has remained controversial, with several studies
suggesting that some or all of these cells constitutively express at least one compo-
nent of the IL-2 receptor (28, 30, 31) . By comparison, it has been known for some
time that freshly isolated NK cells respond to IL-2 with increases in non-MHC-
restricted cytotoxicity (2-4) and proliferation (32-35), without apparent prior an-
tigen activation . Despite the functional responsiveness to IL-2, the phenotypic ex-
pression ofthe p55 chain has never been detectable on restingNK cells (32-34, 36-38) .
In contrast, it has recently been shown that the majority ofNK cells constitutively
express the isolated intermediate affinity p75 IL-2 receptor, and that blocking of
this receptor abrogates the IL-2-mediated enhancement of cytolytic activity (23) .
Even so, the proliferative response ofNK cells that has been observed at very low
concentrations of IL-2 has not been conclusively shown to occur through this inter-
mediate affinity IL-2 receptor (23, 39) . To assess the functional responsiveness of
restingpopulations ofT cells and NK cells and to identify which receptor form mediates
these responses, we undertook a detailed analysis of these cells using radiolabeled
IL-2 binding assays, Northern blot analyses, flow cytometric phenotypic analyses,
as well as IL-2 dose-dependent functional assays of proliferation and cytotoxicity.
Taken together, our studies demonstrate that the vast majority ofT cells lack con-
stitutive expression of either p55 or p75 IL-2 binding sites before antigen activation .
Consequently, incubation of resting T cells with exogenous rIL-2 does not result
in proliferation . After activation with anti-CD3, T cells show a dramatic increase
in the expression of both p75 mRNA and p55 mRNA, which accounts for an ob-
served eightfold increase in the surface expression and subsequent formation ofhigh
affinity IL-2 receptors within the activated T cell population . This rapid induction
of high affinity receptor expression, along with the concomitant production of IL-21520
￿
INTERLEUKIN 2 RECEPTORS IN RESTING LYMPHOCYTES
(40), accounts for the proliferative response observed following activation of T cells
as shown in previous studies (40, 41). As activation ofCD3 is thought to essentially
mimic the signaling events that follow antigenic activation via the CD3TCR com-
plex, thesestudies serve to emphasize not only the role of IL-2 and the IL-2 receptor
in determining the onset and duration of a clonal T cell response after antigen acti-
vation, but also the equally critical absence of IL-2 reactivity by T cells before an-
tigen activation. Thus, the specificity of the T cell response appears to be tightly
regulated by antigen-induced expressionof both chains comprising the IL-2 receptor.
The expression of the IL-2 receptor within the NK cell population is distinctly
different from that seen within the T cell population. Taken together, binding studies,
Northern blot analyses, and phenotypic analyses strongly suggest that the majority
of NK cells constitutively express isolated intermediate affinity p75 IL-2 receptor.
The variable expression of p75 seen within the NKHI + population (i.e., 29 ± 19%
positive cells) appears to be a limitation ofthe flow cytometric analysis (19, 23). These
cells undoubtedly express numbers of isolated p75 IL-2 receptors that are barely
detectable by standard flow cytometric methods. In addition to the constitutive ex-
pression of this intermediate affinity receptor, NK cells appear to be heterogeneous
with regard to the expression of a functional high affinity receptor as defined by
their marked proliferative response to low concentrations of IL-2 that only saturate
high affinity IL-2 receptor sites. Again, due to low density expression of this receptor,
this subpopulation of NK cells cannot be reproducibly detected using mAbs specific
for the p55 chain of the heterodimeric high affinity IL-2 receptor. However, they
can be isolated from the remainder of resting PBL by their unique high density sur-
face expression of the NKH1 antigen. Careful purification of CD4+ and CD8+ T
cell subsets, B cells, and NK cells (based on density expression of the NKHl an-
tigen) failed to demonstrate any other lymphoid population within resting human
peripheral blood with constitutive expression of a functional high affinity IL-2
receptors, as measured by proliferation in response to exogenous IL-2 without addi-
tional activation.
Importantly, by examining the proliferative responsiveness of both NKHI b6ght+
cells and NKH1d " cells at increasing doses of IL-2, we were able to demonstrate
that the constitutive expression of the high affinity IL-2 receptor found only within
the NKHlb"gh`+ population is responsible for the great majority of NK cell prolifer-
ation seen when resting peripheral blood is incubated with IL-2. Moreover, the iso-
lated intermediate affinity p75 IL-2 receptor, expressed in the absence of the high
affinity IL-2 receptor on NKHld'm+ cells, appears to transduce only a minimal
growth signal, despite addition ofsaturatingconcentrations of IL-2 and the demon-
stration of the receptor's functional competency in cytotoxicity assays. Given that
the NKHIbr'gh,+ population represents only ti3-5% of NK cells and therefore only
-0.3-0.5% of PBMC, it is clear that only a very small fraction of resting peripheral
blood cells have the capacity to generate a significant proliferative response to physi-
ologic concentrations of IL-2 in the absence of antigen activation.
The present model of the IL-2 receptor suggests that signal transduction depends
upon the p75 chain, whether expressed in its isolated intermediate affinity form or
as part of the heterodimeric high affinity receptor. Accordingly, this model dictates
that fully saturated isolated intermediate affinity p75 IL-2 receptors should trans-
duce similar signals for growth as does the high affinity IL-2 receptor when fullyCALIGIURI ET AL.
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saturated. Data supporting this interpretation come from experiments measuring
proliferation of activated T cells expressing high affinity IL-2 receptors: in the pres-
ence of excess anti-p55, the high affinity heterodimeric IL-2 receptor structure is
disrupted, and the dose-response curve shifts, showing a similarmaximal prolifera-
tive response but requiring -100-fold greater concentrations of IL-2 to saturate the
newly created isolated intermediate affinity IL-2 receptors. Thesedata arealso con-
sistent with affinity binding studies performed on cell lines expressing only the in-
termediate affinity p75 IL-2 receptor (17). Nevertheless, recent attempts to construct
a high affinity IL-2 receptor by transfection of both the p75 and p55 cDNA into
COS cellsfailed to demonstrateIL-2 bindingcharacteristic ofthe high affinity receptor,
suggesting that this structure may have additional components (16). Using NKHldim+
cells freshly isolated from restinghumanperipheral blood, ourcurrent studies show
that the IL-2 proliferative signal in cells constitutively expressing the intermediate
affinity p75 IL-2 receptor without the high affinity IL-2 receptor is not equivalent
to that seen in NKHlbrigh,+ cells that also express the high affinity IL-2 receptor,
despite concentrations of IL-2 that resulted in 100% saturation of the isolated p75
IL-2 receptor. Additionally, NKH1bright I cells did not increase their proliferation
at doses of IL-2 that saturate the isolated p75 chain, despite the phenotypically de-
tectable excess of p75 IL-2 receptors expressed on their surface. While the explana-
tion for this is not clear, these data strongly argue against receptor affinity as being
the only functional difference between these two classes of receptors, and suggest
that there may be additional, and as yet unknown, characteristics of the isolated
p75 IL-2 receptor that affect its ability to transduce a proliferative signal. Data
presented here, using populations of restinghuman peripheral blood NK cells, would
suggest that additional undetected structures might be involved in the formation
of the high affinity IL-2 receptor, or that the noncovalent bondingof the p55 chain
to the p75 chain may somehow alter the post-ligand signal. Alternatively, it is also
possible that the NKHldim+ and NKHlb"gh,+ cells represent distinct populations that
might therefore transmit different post-ligand signals after IL-2 binding to the iso-
lated intermediate affinity p75 IL-2 receptor. This latter explanation seems unlikely,
as proliferation of the NKH1bright+ population is not increased at doses of IL-2 that
completely saturate the isolated 75 chain, known to be expressed in excess on the
NKHIbright+ cell surface.
Thereasons for the constitutive expression ofthe intermediate affinity IL-2 receptor
on NK cells in restingperipheral bloodremain unresolved. It is known that enhance-
ment of cytotoxicity can occur exclusively through the isolated p75 chain (23, 39).
Thus, for the NKHlbrigh,+ cells that constitutively express both the high affinity and
intermediate affinity IL-2 receptors, low concentrations of IL-2 result in prolifera-
tion of this population, while higher concentrations of IL-2 are also able to activate
the cytolytic mechanism of these cells. The fact that this process occurs in an in-
cremental, dose-response fashion might well be advantageous to the host. Neverthe-
less, it is also evident that, in the absenceof additional activation signals, the majority
of NK cells express only the intermediate affinity IL-2 receptor, and it is unclear
whyIL-2 can readily promote the enhanced cytotoxicity ofthis subpopulationwithout
comparable stimulation of their proliferation. It is certainly possible that additional
cell-cell interactions and/or other lymphokines are involved in the generation of a
proliferative response in vivo.1522
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The constitutive expression of a functional high affinity IL-2 receptor on a subset
of NK cells without prior activation suggests that these cells undergo a polyclonal
proliferative response to physiologic concentrations of IL-2. Hence, although both
activated T cells and NKHlbright+ cells use the high affinity IL-2 receptor to pro-
liferate in response to IL-2, the NK cell fraction constitutively expresses this receptor
without priorantigen activation, while the T cell can only express this receptor and
respond to IL-2 after antigen activation. This differential use of the receptor may
lend some insights into the distinct functionalroles for these two populations in vivo.
There is extensive experimental (42-46) and limited clinical (47) information that
suggest that NK cells play an important role in the early response to viral infection,
acting as a first line of defense capable o£ responding nonspecifically to virus-infected
cells before a specific T cell response can be generated. Our data demonstrating
the constitutive expression of a functional high affinity IL-2 receptor within the
NKHlbright+ population of resting peripheral blood, while resting T cells lack any
such receptor, would strongly support this hypothesis and provide a mechanism
whereby this may occur in vivo. Also consistent with the idea that NK cells provide
a first line of defense is the fact that NK cells do not express a clonotypic CD3TCR
(48). The recent finding that NK cells express the ~ chain of the TCR (49) suggests
that NK cells may represent an evolutionary forerunner of clonotypic T cells, but
NK cells have nevertheless retained a place in the human immune defense system
(50). Our demonstration of a subset of NK cells that constitutively express a func-
tional high affinity IL-2 receptor in resting human peripheral blood similar to that
seen on T cells after antigen activation helps to explain how such cells may be able
to respond quickly to the presence of virus-transformed cells or other target cells.
The expression of different IL-2 receptor forms with functionally distinct conse-
quences as now seen on subpopulations ofNK cells should help us to further charac-
terize these lymphocytes with regard to their function in vivo. Thus, our data help
to explain why freshly isolated NKHl bright+ cells show a greater proliferative re-
sponse to IL-2 when compared with the NKHldi,+ population as previously re-
ported (25, 51, 52), and why clinical studies often show an increase in the
NKHlbright+ population after low dose infusion of rIL-2: presumably .only cells ex-
pressing the high affinity IL-2 receptor can proliferate to what must be very low
serum concentrations of IL-2. Furthermore, the information gained from the data
presented here should now assist us in the future development of rational clinical
trials whereby large numbers of NK cells may be generated in vivo with prolonged
infusions ofrelatively low doses of IL-2 that saturate only the high affinity IL-2 receptor
constitutively expressed on the NKHlbright+ Cells. Subsequent induction of non-
MHC-restricted cytotoxicity via the isolated intermediate affinity p75 IL-2 receptor
also expressed on these cells might then be undertaken at regular intervals to pro-
mote tumor cytolysis with less clinical toxicity.
Summary
In this study, we have used radiolabeled IL-2 binding assays, Northern blot anal-
ysis, immunofluorescent flow cytometry and cell sorting, as well as proliferation and
cytotoxicity assays to perform an extensive phenotypic and functional characteriza-
tion of the IL-2 receptor in normal resting human peripheral blood lymphocytes.
Our results indicate that almost all T cells (>98%) express neither the high affinityCALIGIURI ET AL.
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IL-2 receptor nor the functional intermediate affinity p75 chain ofthe IL-2 receptor
without prior activation . In contrast, most NK cells constitutively express the iso-
lated intermediate affinity p75 IL-2 receptor. In addition, a subpopulation of NK
cells, distinguished by high density expression of the NKH1 antigen, constitutively
express the high affinity IL-2 receptor, in addition to an excess ofthe isolated inter-
mediate affinity p75 IL-2 receptor. These NKH16"sh'+ cells exhibit a brisk prolifer-
ative response to IL-2, similar to that seen with antigen-activated T cells, yet do
so in the absence of any known antigenic stimuli. No other resting peripheral blood
lymphocyte population, including CD4+, CD8+ , and CD20 cells, exhibits this prop-
erty. The intermediate affinity p75 IL-2 receptor, as it exists in its isolated form
on resting NK cells, does not transduce a growth signal equivalent to that seen in
NK cells expressing the high affinity IL-2 receptor, despite doses of IL-2 that are
known to fully saturate the isolated p75 chain . This strongly suggests that additional
structural or functional components are involved in generating the proliferative re-
sponse following the binding of IL-2 to the high affinity heterodimeric form of the
IL-2 receptor. The constitutive expressionofthis functional high affinity IL-2 receptor
on a small population of resting NK cells provides further evidence in support of
a role for these cells in the host's early defense against viral infection or malignant
transformation, before the more delayed but specific T cell response.
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